Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LS301-IT for Fluorescence Imaging in Lung Cancer Resection
NCT07276789Phase 2Active, not recruiting
- Sponsor
- Integro Theranostics
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of ls301 in non-small cell lung cancer (NSCLC), sponsored by Integro Theranostics. Started Dec 2025; status: active, not recruiting.
02
Drugs
ls301
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07276789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07276789.